References
- Von Roemeling R., Hrushesky W. J. M. Orcadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin. Oncol. 1989; 7: 1710–1719
- Caussanel J. P., Levi F., Brienza S., et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046–1050
- Hrushesky W. J. M., Von Roemeling R., Lanning R. M., Rabatin J. T. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J. Clin. Oncol. 1990; 8: 1504–1513
- Damascielli B., Marchiano A., Spreafico C, et al. Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. Cancer 1990; 66: 237–241
- Levi F., Benavides M., Chevelle C, et al. Chemotherapy of advanced ovarian cancer with 4′-0-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J. Clin. Oncol. 1990; 8: 705–714
- Boughattas N. A., Levi F., Fournier C., et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diammino-cyclohexane (trans- 1)oxalatoplatinum (II) in mice. Cancer Res 1989; 49: 3362–3368
- Boughattas N. A., Levi F., Fournier C., et al. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J. Pharmacol Exp. Ther. 1990; 255: 672–679
- Harris B. E., Song R., Soong S. J., Diasio R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197–201